Medications for Infantile Spasms

6 results

  • Sabril (vigabatrin)

    (vigabatrin)
    Lundbeck Pharmaceuticals LLC
    Usage: SABRIL is indicated as adjunctive therapy for adults and children (2 years and older) with refractory complex partial seizures and as monotherapy for infants (1 month to 2 years) with infantile spasms, where benefits outweigh the risk of vision loss. Not a first-line treatment for complex partial seizures.

  • Vigabatrin (vigabatrin)

    (vigabatrin)
    Zydus Lifesciences Limited
    Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for refractory complex partial seizures in adults and children (2 years and older) not responding to other treatments, and as monotherapy for infantile spasms in children (1 month to 2 years). Vision loss risks must be considered.

  • Vigabatrin (vigabatrin)

    (vigabatrin)
    Cipla USA, Inc.
    Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for refractory complex partial seizures in patients 2 years and older, and as monotherapy for infantile spasms in children 1 month to 2 years old, where benefits outweigh the risks of vision loss.

  • Vigabatrin (vigabatrin)

    (Vigabatrin)
    Lupin Pharmaceuticals Inc
    Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for refractory complex partial seizures in patients aged 2 and older, and as monotherapy for infantile spasms in children aged 1 month to 2 years, when the benefits outweigh the risk of vision loss.

  • Vigabatrin (vigabatrin)

    (vigabatrin)
    Zydus Pharmaceuticals (USA) Inc.
    Usage: Vigabatrin is indicated as adjunctive therapy for adults and children (2 years and older) with refractory complex partial seizures, and as monotherapy for pediatric patients (1 month to 2 years) with infantile spasms. Vision loss risks must be considered against potential benefits. Not a first-line treatment for CPS.

  • Vigabatrin (vigabatrin)

    (vigabatrin)
    Novadoz Pharmaceuticals LLC
    Usage: Vigabatrin for oral solution is indicated as adjunctive therapy for adults and pediatric patients (2 years and older) with refractory complex partial seizures and as monotherapy for infants (1 month to 2 years) with infantile spasms, when potential benefits outweigh the risk of vision loss.